GlassScriptPhysician profile
Andrew Berglund
NPI 1346669199
$1,554.28
in general payments reported to CMS, 2019-2025
15 companies · $229 in 2025
The $229 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99.99 · 2020: $217 · 2021: $173 · 2022: $37.87 · 2023: $609 · 2024: $189 · 2025: $229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,010 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,009.57 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $449.48 | 2020-2023 | Tezspire, Fasenra |
| Amgen INC. | $284.64 | 2023-2024 | Tezspire |
| Ge Healthcare | $148.94 | 2024 | |
| Verona Pharma, INC. | $145.12 | 2025 | Ohtuvayre |
| Acacia Pharma INC | $121.94 | 2021 | |
| Genentech USA, INC. | $99.99 | 2019 | |
| Genzyme Corporation | $55.41 | 2021-2023 | |
| Insmed, INC. | $53.51 | 2025 | Arikayce, Brinsupri |
| Biofire Diagnostics, LLC | $40.00 | 2020 | |
| Philips North America LLC | $31.29 | 2023-2024 | (Ck4) Mcot |
| Pulmonx Corporation | $30.85 | 2025 | Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.05 | 2023 | Ofev |
| Arbor Pharmaceuticals, INC. | $26.24 | 2020 | |
| Pfizer INC. | $24.39 | 2020-2022 | |
| Boston Scientific Corporation | $14.43 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Berglund listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.